Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05360628 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of PK and Safety of D-0120 and Allopurinol
A Early Phase 1 study, sponsored by InventisBio Co..
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT05360628 is a Early Phase 1 study that has completed, run by InventisBio Co.. The registered enrollment target is 20 participants.
The verdict
NCT05360628, a Early Phase 1 study, has completed, sponsored by InventisBio Co..
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Evaluation of safety and PK interaction between D-0120 and Alopurinol in healthy adult subjects
Interventions
- DRUG D-0120 in combination with Allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2022-07-23 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05360628
The ClinicalTrials.gov registry entry for NCT05360628 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InventisBio Co., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which D-0120 in combination with Allopurinol is the first listed.
NCT05360628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05360628 about?
NCT05360628 is a clinical study titled "Evaluation of PK and Safety of D-0120 and Allopurinol". Evaluation of safety and PK interaction between D-0120 and Alopurinol in healthy adult subjects
What is the current status of trial NCT05360628?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2021-11-01. Estimated completion is 2022-07-23.
What interventions are being tested in trial NCT05360628?
The interventions under investigation include: D-0120 in combination with Allopurinol (DRUG).
Who is sponsoring clinical trial NCT05360628?
This trial is sponsored by InventisBio Co., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.